1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). January 2015.http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf(accessed September 15 2015).
2. Boehringer Ingelheim Pharmaceuticals Inc. Atrovent HFA (ipratropium bromide HFA) inhalation aerosol full prescribing information. August 2012.http://docs.boehringer‐ingelheim.com/Prescribing%20Information/PIs/Atrovent%20HFA/10003001_US_1.pdf?DMW_FORMAT=pdf(accessed September 15 2015).
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Global Initiative for Asthma. April 2015.http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_Aug11.pdf(accessed September 15 2015).
4. In Chronic Obstructive Pulmonary Disease, a Combination of Ipratropium and Albuterol Is More Effective Than Either Agent Alone
5. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two‐in‐one inhaler versus separate inhalers;Chrischilles E.;Am. J. Manag. Care,2002